Australia markets closed

Zhejiang Shengda Bio-Pharm Co., Ltd. (603079.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
12.26+0.13 (+1.07%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 2.08B
Enterprise value 2.08B
Trailing P/E 74.33
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.82
Price/book (mrq)1.67
Enterprise value/revenue 2.80
Enterprise value/EBITDA 18.32

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-4.26%
S&P500 52-week change 326.36%
52-week high 316.24
52-week low 37.01
50-day moving average 311.20
200-day moving average 312.55

Share statistics

Avg vol (3-month) 37.97M
Avg vol (10-day) 319.4M
Shares outstanding 5171.19M
Implied shares outstanding 6171.19M
Float 872.81M
% held by insiders 159.46%
% held by institutions 10.57%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.06
Forward annual dividend yield 40.49%
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 40.90
Payout ratio 4175.00%
Dividend date 3N/A
Ex-dividend date 425 May 2023
Last split factor 21.4:1
Last split date 308 June 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -7.43%
Operating margin (ttm)4.06%

Management effectiveness

Return on assets (ttm)-0.10%
Return on equity (ttm)-4.15%

Income statement

Revenue (ttm)727.41M
Revenue per share (ttm)4.31
Quarterly revenue growth (yoy)9.20%
Gross profit (ttm)N/A
EBITDA 69.3M
Net income avi to common (ttm)-54.06M
Diluted EPS (ttm)-0.32
Quarterly earnings growth (yoy)9.20%

Balance sheet

Total cash (mrq)284.81M
Total cash per share (mrq)1.68
Total debt (mrq)285.28M
Total debt/equity (mrq)22.60%
Current ratio (mrq)2.35
Book value per share (mrq)7.36

Cash flow statement

Operating cash flow (ttm)64.42M
Levered free cash flow (ttm)-140.59M